OVERVALUEDNASDAQ · Healthcare

Arbutus Biopharma Corporation

ABUS

FAIR PRICE VALUATION

48.5%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$4.54

FAIR PRICE

$2.34

MARGIN

$2.20

UNDERVALUEDFAIROVERVALUED

P/E Ratio

N/A

Div. Yield

N/A

ROE

-42.4%

Average

Market Cap

$880M

Small-cap

COMING SOON

Get notified when ABUS's fair price changes

Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.

iOS and Android · Free tier available

KEY FACTS

CEO

Lindsay Androski

COUNTRY

US

HEADQUARTERS

Warminster

SECTOR

Healthcare

EXCHANGE

NASDAQ

METHODOLOGY

How we calculate ABUS's fair price

Arbutus Biopharma Corporation's fair price of $2.34 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $4.54, ABUS trades 48.5% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ABUS's risk profile.

RELATIVE · 30%

Comparing ABUS's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for ABUS, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate ABUS's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for ABUS.

Explore on Bulios

FAQ

What is the fair price of ABUS?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Arbutus Biopharma Corporation is $2.34. At the current market price of $4.54, ABUS trades 48.5% above its calculated fair value.

Is ABUS overvalued or undervalued?+

Arbutus Biopharma Corporation is currently overvalued based on our valuation model. The stock trades at $4.54, which is 48.5% above the fair price of $2.34.

How often is ABUS's fair price updated?+

We update fair price calculations for ABUS daily after market close. The current fair price of $2.34 incorporates the latest market data and sector multiples.

What factors affect ABUS's fair price calculation?+

ABUS's fair price of $2.34 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -42.4%.

Is ABUS a good buy right now?+

At $4.54, ABUS trades 48.5% above our fair value estimate of $2.34. The stock is currently overvalued. ROE stands at -42.4% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does ABUS pay dividends?+

ABUS does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.